	US 12,251,377 B2
	Anticoagulant compositions and uses thereof
Michael P. Eaton, Rochester, NY (US)
Assigned to University of Rochester, Rochester, NY (US)
Appl. No. 17/436,270
Filed by University of Rochester, Rochester, NY (US)
PCT Filed Feb. 19, 2020, PCT No. PCT/US2020/018717 § 371(c)(1), (2) Date Sep. 3, 2021, PCT Pub. No. WO2020/180489, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/814,454, filed on Mar. 6, 2019.
Prior Publication US 2022/0175748 A1, Jun. 9, 2022
Int. Cl. A61K 31/4439 (2006.01); A61K 39/395 (2006.01); A61P 7/02 (2006.01); C07K 16/44 (2006.01)

CPC A61K 31/4439 (2013.01) [A61K 39/39583 (2013.01); A61P 7/02 (2018.01); C07K 16/44 (2013.01)]

13 Claims

1. A method for managing or inhibiting blood coagulation during a procedure in a subject, comprising administering parenterally to the subject or the blood thereof an effective amount of dabigatran so that the blood dabigatran concentration is about 500 ng/ml to about 30,000 ng/ml, and wherein the procedure is a cardiopulmonary bypass procedure or an extracorporeal circulation procedure.